Skip to main content
SpringerLink
Log in

Recombinant Full-Length Parathyroid Hormone (1–84)

Profile Report

  • Adis Profile Report
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Moen MD, Scott LJ. Recombinant full-length parathyroid hormone (1-84). Drugs 2006; 66(18): 2371–2381

    Article  PubMed  CAS  Google Scholar 

  2. Whitfield, J. Recombinant full-length parathyroid hormone (1-84): a viewpoint. Drugs 2006; 66(18): 2382–2385

    Article  Google Scholar 

  3. Hanley DA. Recombinant full-length parathyroid hormone (1-84): a viewpoint. Drugs 2006; 66(18): 2382–2385

    Article  Google Scholar 

  4. Hosking D. Recombinant full-length parathyroid hormone (1-84): a viewpoint. Drugs 2006; 66(18): 2382–2385

    Article  Google Scholar 

  5. Felsenberg D. Recombinant full-length parathyroid hormone (1-84): a viewpoint. Drugs 2006; 66(18): 2382–2385

    Article  Google Scholar 

  6. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005 Dec; 115(12): 3318–25

    Article  PubMed  CAS  Google Scholar 

  7. Delmas PD, Rizzoli R, Cooper C, et al. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 2005 Jan; 16(1): 1–5

    Article  PubMed  Google Scholar 

  8. McClung M. Parathyroid hormone for the treatment of osteoporosis. Obstet Gynecol Surv 2004; 59(12): 826–32

    Article  PubMed  Google Scholar 

  9. Murray TM, Rao LG, Divieti P, et al. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. Endocr Rev 2005 Feb; 26(1): 78–113

    Article  PubMed  CAS  Google Scholar 

  10. Nycomed. Preotact (full-length parathyroid hormone): product information (EU) [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/preotact/preotactM.htm [Accessed 2007 May 9]

  11. Moreau IA, Smith SY, Guldberg RE, et al. Treatment of osteopenic rhesus monkeys with parathyroid hormone 1-84 for 16 months improves vertebral trabecular bone quantity and quality [abstract no. M415]. J Bone Miner Res 2005 Sep; 20Suppl. 1: S412

    Google Scholar 

  12. Kimmel DB, Bozzato RP, Kronis KA, et al. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 1993 Apr; 132(4): 1577–84

    Article  PubMed  CAS  Google Scholar 

  13. Whitfield JF, Morley P, Willick GE, et al. Comparison of the ability of recombinant human parathyroid hormone, rhPTH-(1-84), and hPTH-(1-31)NH2 to stimulate femoral trabecular bone growth in ovariectomized rats. Calcif Tissue Int 1997 Jan; 60(1): 26–9

    Article  PubMed  CAS  Google Scholar 

  14. Ejersted C, Andreassen TT, Oxlund H, et al. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res 1993 Sep; 8(9): 1097–101

    Article  PubMed  CAS  Google Scholar 

  15. Samnegard E, Iwaniec UT, Cullen DM, et al. Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats. Bone 2001 Mar; 28(3): 251–60

    Article  PubMed  CAS  Google Scholar 

  16. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Treatment of Osteoporosis with Parathyroid Hormone Study Group. Ann Intern Med 2007 Mar 6; 146(5): 326–39

    PubMed  Google Scholar 

  17. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005 Aug 11; 353(6): 555–65

    Article  PubMed  CAS  Google Scholar 

  18. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003 Sep 25; 349(13): 1207–15

    Article  PubMed  CAS  Google Scholar 

  19. Fogelman I, Christiansen C, Spector T, et al. Safety and efficacy of PTH(1-84) at 18 and 24 months in women with postmenopausal osteoporosis receiving hormone therapy: results from the POWER study [abstract no. 1080]. J Bone Miner Res 2005 Sep; 20Suppl. 1: S21–2

    Google Scholar 

  20. Tregear GW, vanRietschoten J, Greene E, et al. Solid-phase synthesis of the biologically active N-terminal 1-34 peptide of the human parathyroid hormone. Hoppe Seylers Z Physiol Chem 1974; 355(4): 415–421

    Article  PubMed  CAS  Google Scholar 

  21. Whitfield JF. Osteoporosis-treating parathyroid hormone peptides: What are they? What do they do? How do they do it? Curr Opin Invest Drugs 2006; 7(4): 349–359

    CAS  Google Scholar 

  22. NPS® Pharmaceuticals. NPS receives approvable letter for PREOS NDA. 2006 Mar 10 [online]. Available from URL: http://www.npsp.com/news/releasetxt.php?ReqId=830043 [Accessed 2006 Nov 15]

  23. Whitfield JF, Morley P, Willick G, et al. Stimulation of the growth of femoral trabecular bone in ovariectomized rats by the novel parathyroid hormone fragment hPTH-(1-31)NH2 (ostabolin). Calcif Tissue Int 1996; 58(2): 81–87

    Article  PubMed  CAS  Google Scholar 

  24. Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004; 32(4): 426–438

    Article  PubMed  CAS  Google Scholar 

  25. Morley P. Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin Drug Deliv 2005; 2(6): 993–1002

    Article  PubMed  CAS  Google Scholar 

  26. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26(5): 688–703

    Article  PubMed  CAS  Google Scholar 

  27. Hodsman A, Papaioannou A, Cranney A. Scientific Advisory Council of Osteoporosis Canada, Clinical Guidelines Committee, Writing Group on the Systematic Review of Parathyroid Hormone for the Treatment of Osteoporosis. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis. CMAJ 2006 Jul 4; 175(1): 48

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ¦ Adis, 41 Centori-an Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Marit D. Moen & Lesley J. Scott

Authors
  1. Marit D. Moen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marit D. Moen.

Additional information

Adapted and reproduced from Drugs 2006; 66 (18): 2371–2385. [1–5] The manufacturer of the agent under review was offered an opportunity to comment on the original article[1] during the peer review process; changes based on any comments received were made on the basis of scientific and editorial merit

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moen, M.D., Scott, L.J. Recombinant Full-Length Parathyroid Hormone (1–84). BioDrugs 21, 205–208 (2007). https://doi.org/10.2165/00063030-200721030-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200721030-00009

Keywords

Search

Navigation